Literature DB >> 21963483

Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Paula L Vieira-Brock1, Eleanor I Miller, Shannon M Nielsen, Annette E Fleckenstein, Diana G Wilkins.   

Abstract

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of nicotine (NIC), cotinine (COT), nornicotine (NNIC), norcotinine (NCOT), nicotine-N-β-D-glucuronide (NIC GLUC), cotinine-N-β-D-glucuronide (COT GLUC), nicotine-1'-oxide (NNO), cotinine-N-oxide (CNO), trans-3'-hydroxycotinine (3-HC), anabasine (AB) and anatabine (AT) was modified and validated for quantification of these selected analytes in rat brain tissue. This analytical method provides support for preclinical NIC pharmacokinetic and toxicological studies after controlled dosing protocols. After brain homogenization and solid-phase extraction, target analytes and corresponding deuterated internal standards were chromatographically separated on a Discovery(®) HS F5 HPLC column with gradient elution and analyzed by LC-MS/MS in positive electrospray ionization (ESI) mode with multiple reaction monitoring (MRM) data acquisition. Method linearity was assessed and calibration curves were determined over the following ranges: 0.1-7.5 ng/mg for NIC, COT GLUC and AB; and 0.025-7.5 ng/mg for COT, NNIC, NCOT, NIC GLUC, NNO, CNO, 3-HC and AT (R(2)≥0.99 for all analytes). Extraction recoveries ranged from 64% to 115%, LC-MS/MS matrix effects were ≤21%, and overall process efficiency ranged from 57% to 93% at low and high quality control concentrations. Intra- and inter-assay imprecisions and accuracy for all analytes were ≤12.9% and ≥86%, respectively. The method was successfully applied to quantification of NIC and metabolites in the brain of post-natal day 90 rats that were sacrificed 2-h after a single 0.8 mg/kg s.c. administration of (-)NIC. In these tissues, striatal concentrations were 204.8±49.4, 138.2±14.2 and 36.1±6.1 pg/mg of NIC, COT and NNIC, respectively. Concentrations of NIC, COT and NNIC in the remaining whole brain (RWhB) were 183.3±68.0, 130.0±14.1 and 46.7±10.3 pg/mg, respectively. Quantification of these same analytes in plasma was also performed by a previously validated method. NIC, COT, NNIC, NCOT, NNO and CNO were detected in plasma with concentrations comparable to those reported in previous studies. However, and in contrast to brain tissues, COT concentrations in plasma were significantly higher than were those of NIC (194.6±18.6 ng/mL versus 52.7±12.9 ng/mL). Taken together, these results demonstrate that a sensitive and selective method has been developed for the determination of NIC biomarkers in rat brain. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963483      PMCID: PMC3210385          DOI: 10.1016/j.jchromb.2011.09.026

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  39 in total

1.  Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition.

Authors:  Jian Guo; Diansong Zhou; Scott W Grimm
Journal:  J Pharm Biomed Anal       Date:  2011-03-29       Impact factor: 3.935

Review 2.  Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking.

Authors:  P A Crooks; L P Dwoskin
Journal:  Biochem Pharmacol       Date:  1997-10-01       Impact factor: 5.858

3.  (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner.

Authors:  L P Dwoskin; L Teng; S T Buxton; P A Crooks
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

Review 4.  Molecular genetics of nicotine metabolism.

Authors:  Jill C Mwenifumbo; Rachel F Tyndale
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Chronic high dose transdermal nicotine in Parkinson's disease: an open trial.

Authors:  G Villafane; P Cesaro; A Rialland; S Baloul; S Azimi; C Bourdet; J Le Houezec; I Macquin-Mavier; P Maison
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

Review 6.  Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.

Authors:  Neal L Benowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

Review 7.  CYP2A6 polymorphisms and risk for tobacco-related cancers.

Authors:  Ana Rossini; Tatiana de Almeida Simão; Rodolpho Mattos Albano; Luis Felipe Ribeiro Pinto
Journal:  Pharmacogenomics       Date:  2008-11       Impact factor: 2.533

8.  Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.

Authors:  Tanuja Bordia; Carla Campos; Luping Huang; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2008-07-23       Impact factor: 4.030

9.  Effect of anabasine on catecholamine secretion from the perfused rat adrenal medulla.

Authors:  Soon-Pyo Hong; Min-Gyoo Jeong; Dong-Yoon Lim
Journal:  J Cardiol       Date:  2007-12       Impact factor: 3.159

Review 10.  Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.

Authors:  Steven D Buckingham; Andrew K Jones; Laurence A Brown; David B Sattelle
Journal:  Pharmacol Rev       Date:  2009-03-16       Impact factor: 25.468

View more
  12 in total

1.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

Review 2.  The chemical components of electronic cigarette cartridges and refill fluids: review of analytical methods.

Authors:  Marco Famele; Carolina Ferranti; Carmelo Abenavoli; Luca Palleschi; Rosanna Mancinelli; Rosa Draisci
Journal:  Nicotine Tob Res       Date:  2014-09-25       Impact factor: 4.244

3.  The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Luisa Ponzoni; Daniela Braida; Luca Pucci; Donzelli Andrea; Francesca Fasoli; Irene Manfredi; Roger L Papke; Clare Stokes; Giuseppe Cannazza; Francesco Clementi; Cecilia Gotti; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2014-05-27       Impact factor: 4.530

4.  Quantitation of cotinine and its metabolites in rat plasma and brain tissue by hydrophilic interaction chromatography tandem mass spectrometry (HILIC-MS/MS).

Authors:  Pei Li; Wayne D Beck; Patrick M Callahan; Alvin V Terry; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-09-15       Impact factor: 3.205

5.  Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.

Authors:  Evelyn L Craig; Bin Zhao; Jason Z Cui; Maria Novalen; Sharon Miksys; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-06-30       Impact factor: 3.922

6.  Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.

Authors:  Michael J Marks; Heidi C O'Neill; Kelly M Wynalda-Camozzi; Nick C Ortiz; Emily E Simmons; Caitlin A Short; Christopher M Butt; J Michael McIntosh; Sharon R Grady
Journal:  Neuropharmacology       Date:  2015-07-17       Impact factor: 5.250

7.  Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration.

Authors:  Kristine L P Garcia; Kathy Coen; Sharon Miksys; Anh Dzung Lê; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-02-05       Impact factor: 7.853

8.  VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Authors:  P K Multani; R Hodge; M A Estévez; T Abel; H Kung; M Alter; B Brookshire; I Lucki; A H Nall; K Talbot; G A Doyle; F W Lohoff
Journal:  Neuroscience       Date:  2012-11-29       Impact factor: 3.590

9.  Age-related differences in the disposition of nicotine and metabolites in rat brain and plasma.

Authors:  Paula L Vieira-Brock; David M Andrenyak; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  Nicotine Tob Res       Date:  2013-06-04       Impact factor: 4.244

10.  Simultaneous quantification of tobacco alkaloids and major phase I metabolites by LC-MS/MS in human tissue.

Authors:  Lisa Fischer; Felix Mikus; Ricarda Jantos; Gisela Skopp
Journal:  Int J Legal Med       Date:  2014-10-11       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.